Pfizer's novel glaucoma candidate goes to trial

Article

Pfizer has initiated the first in a series of planned clinical trials for PF-03187207, a new experimental medicine for the treatment of glaucoma.

Pfizer has initiated the first in a series of planned clinical trials for PF-03187207, a new experimental medicine for the treatment of glaucoma.

The Phase II, dose-finding study, will compare the safety and efficacy of PF-03187207 to latanoprost over a 28-day period. The randomized, double-masked study is expected to enrol 150 subjects with primary open angle glaucoma or ocular hypertension in one or both eyes.

PF-03187207 is the lead development compound generated under the August 2004 collaboration agreement between NicOx and Pfizer, which focuses on the research and development of nitric oxide-donating prostaglandin F2-alpha analogues for the treatment of glaucoma.

The initiation of the clinical trial follows the granting of an Investigational New Drug (IND) approval by the FDA, which in turn results in a €1 million milestone payment from Pfizer to NicOx.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.